Role of the C-Terminal Region of Vervet Monkey Polyomavirus 1 VP1 in Virion Formation
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Polyomavirus Major Capsid Protein VP1 Interacts with the Nuclear Matrix Regulatory Protein
FEBS 23316 FEBS Letters 467 (2000) 359^364 View metadata, citation and similar papers at core.ac.uk brought to you by CORE The polyomavirus major capsid protein VP1 interacts with theprovided nuclearby Elsevier - Publisher Connector matrix regulatory protein YY1 Zdena Palkova¨a;b, Hana Sípanielova¨b, Vanesa Gottifredia;1, Dana Hollanderova¨b, Jitka Forstova¨b, Paolo Amatia;* aInstituto Pasteur - Fondazione Cenci Bolognetti, Dipartimento di Biotecnologie Cellulari ed Ematologia, Sezione di Genetica Molecolare, Universita© di Roma La Sapienza, Viale Regina Elena 324, 00161 Rome, Italy bDepartment of Genetics and Microbiology, Faculty of Natural Sciences, Charles University, Vinie©na¨ 5, 12844 Prague 2, Czech Republic Received 17 December 1999 Edited by Hans-Dieter Klenk The external loops are likely to be the structures involved in Abstract Polyomavirus reaches the nucleus in a still encapsi- dated form, and the viral genome is readily found in association cell receptor recognition by virions [4] and, therefore, to be with the nuclear matrix. This association is thought to be the main antigenic determinants. The £exible C-terminal arms essential for viral replication. In order to identify the protein(s) form interpentameric contacts and the basic amino acids of involved in the virus-nuclear matrix interaction, we focused on the N terminal arm are responsible for the non-speci¢c DNA- the possible roles exerted by the multifunctional cellular nuclear binding activity of VP1 [6,7]. matrix protein Yin Yang 1 (YY1) and by the viral major capsid The necessity for viral genomes to associate to the nuclear protein VP1. In the present work we report on the in vivo matrix (NM) in order to be expressed, has been demonstrated association between YY1 and VP1. -
Cryptic Inoviruses Revealed As Pervasive in Bacteria and Archaea Across Earth’S Biomes
ARTICLES https://doi.org/10.1038/s41564-019-0510-x Corrected: Author Correction Cryptic inoviruses revealed as pervasive in bacteria and archaea across Earth’s biomes Simon Roux 1*, Mart Krupovic 2, Rebecca A. Daly3, Adair L. Borges4, Stephen Nayfach1, Frederik Schulz 1, Allison Sharrar5, Paula B. Matheus Carnevali 5, Jan-Fang Cheng1, Natalia N. Ivanova 1, Joseph Bondy-Denomy4,6, Kelly C. Wrighton3, Tanja Woyke 1, Axel Visel 1, Nikos C. Kyrpides1 and Emiley A. Eloe-Fadrosh 1* Bacteriophages from the Inoviridae family (inoviruses) are characterized by their unique morphology, genome content and infection cycle. One of the most striking features of inoviruses is their ability to establish a chronic infection whereby the viral genome resides within the cell in either an exclusively episomal state or integrated into the host chromosome and virions are continuously released without killing the host. To date, a relatively small number of inovirus isolates have been extensively studied, either for biotechnological applications, such as phage display, or because of their effect on the toxicity of known bacterial pathogens including Vibrio cholerae and Neisseria meningitidis. Here, we show that the current 56 members of the Inoviridae family represent a minute fraction of a highly diverse group of inoviruses. Using a machine learning approach lever- aging a combination of marker gene and genome features, we identified 10,295 inovirus-like sequences from microbial genomes and metagenomes. Collectively, our results call for reclassification of the current Inoviridae family into a viral order including six distinct proposed families associated with nearly all bacterial phyla across virtually every ecosystem. -
Opportunistic Intruders: How Viruses Orchestrate ER Functions to Infect Cells
REVIEWS Opportunistic intruders: how viruses orchestrate ER functions to infect cells Madhu Sudhan Ravindran*, Parikshit Bagchi*, Corey Nathaniel Cunningham and Billy Tsai Abstract | Viruses subvert the functions of their host cells to replicate and form new viral progeny. The endoplasmic reticulum (ER) has been identified as a central organelle that governs the intracellular interplay between viruses and hosts. In this Review, we analyse how viruses from vastly different families converge on this unique intracellular organelle during infection, co‑opting some of the endogenous functions of the ER to promote distinct steps of the viral life cycle from entry and replication to assembly and egress. The ER can act as the common denominator during infection for diverse virus families, thereby providing a shared principle that underlies the apparent complexity of relationships between viruses and host cells. As a plethora of information illuminating the molecular and cellular basis of virus–ER interactions has become available, these insights may lead to the development of crucial therapeutic agents. Morphogenesis Viruses have evolved sophisticated strategies to establish The ER is a membranous system consisting of the The process by which a virus infection. Some viruses bind to cellular receptors and outer nuclear envelope that is contiguous with an intri‑ particle changes its shape and initiate entry, whereas others hijack cellular factors that cate network of tubules and sheets1, which are shaped by structure. disassemble the virus particle to facilitate entry. After resident factors in the ER2–4. The morphology of the ER SEC61 translocation delivering the viral genetic material into the host cell and is highly dynamic and experiences constant structural channel the translation of the viral genes, the resulting proteins rearrangements, enabling the ER to carry out a myriad An endoplasmic reticulum either become part of a new virus particle (or particles) of functions5. -
Ebola Virus VP40 Real-Time RT-PCR Assay for Use Under an Emergency Use Authorization Only
Ebola Virus VP40 Real-Time RT-PCR Assay Centers for Disease Control and Prevention For Use Under an Emergency Use Authorization Only Instructions for Use January 2016 Page 0 of 50 Table of Contents Introduction .................................................................................................................................... 2 Specimens ....................................................................................................................................... 3 Equipment and Consumables ........................................................................................................ 3 Quality Control ............................................................................................................................... 5 Nucleic Acid Extraction ................................................................................................................. 7 Testing Algorithm .......................................................................................................................... 8 rRT-PCR Assay .............................................................................................................................. 9 Interpreting Test Results .............................................................................................................. 14 Overall Test Interpretation and Reporting Instructions ............................................................. 18 Assay Limitations, Warnings and Precautions .......................................................................... -
WHO Expert Committee on Biological Standardization: Sixty-Eighth Report (WHO Technical Report Series, No
This report presents the recommendations of a WHO Expert Committee commissioned to coordinate activities leading to the 1011 adoption of international recommendations for the production WHO Technical Report Series and control of vaccines and other biological substances, and the establishment of international biological reference materials. 1011 Following a brief introduction, the report summarizes a number WHO of general issues brought to the attention of the Committee. The next part of the report, of particular relevance to manufacturers Expert on Biological Standardization Committee and national regulatory authorities, outlines the discussions held on the development and adoption of new and revised WHO Recommendations, Guidelines and guidance documents. Following these discussions, WHO Guidelines on the quality, safety and efficacy of Ebola vaccines, and WHO Guidelines on procedures and data requirements for changes to approved biotherapeutic products were adopted on the recommendation of the Committee. In addition, the following two WHO guidance documents on the WHO prequalification of in vitro diagnostic medical devices were also adopted: (a) Technical Specifications Series (TSS) for WHO Prequalification – WHO Expert Committee Diagnostic Assessment: Human immunodeficiency virus (HIV) rapid diagnostic tests for professional use and/or self- on Biological testing; and (b) Technical Guidance Series (TGS) for WHO Prequalification – Diagnostic Assessment: Establishing stability of in vitro diagnostic medical devices. Standardization Subsequent -
Virus-Host Interaction: the Multifaceted Roles of Ifitms And
Virus-Host Interaction: The Multifaceted Roles of IFITMs and LY6E in HIV Infection DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Jingyou Yu Graduate Program in Comparative and Veterinary Medicine The Ohio State University 2018 Dissertation Committee: Shan-Lu Liu, MD, PhD, Advisor Patrick L. Green, PhD Jianrong Li, DVM., PhD Jesse J. Kwiek, PhD Copyrighted by Jingyou Yu 2018 Abstract With over 1.8 million newly infected people each year, the worldwide HIV-1 epidemic remains an imperative challenge for public health. Recent work has demonstrated that type I interferons (IFNs) efficiently suppress HIV infection through induction of hundreds of interferon stimulated genes (ISGs). These ISGs target distinct infection stages of invading pathogens and shape innate immunity. Among these, interferon induced transmembrane proteins (IFITMs) and lymphocyte antigen 6 complex, locus E (LY6E) have been shown to differentially modulate viral infections. However, their effects on HIV are not fully understood. In my thesis work, I provided evidence in Chapter 2 showing that IFITM proteins, particularly IFITM2 and IFITM3, specifically antagonize the HIV-1 envelope glycoprotein (Env), thereby inhibiting viral infection. IFITM proteins interacted with HIV-1 Env in viral producer cells, leading to impaired Env processing and virion incorporation. Notably, the level of IFITM incorporation into HIV-1 virions did not strictly correlate with the extent of inhibition. Prolonged passage of HIV-1 in IFITM-expressing T lymphocytes led to emergence of Env mutants that overcome IFITM restriction. The ability of IFITMs to inhibit cell-to-cell infection can be extended to HIV-1 primary isolates, HIV-2 and SIVs; however, the extent of inhibition appeared to be virus- strain dependent. -
A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures
viruses Communication A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures Ryan P. Bennett 1,† , Courtney L. Finch 2,† , Elena N. Postnikova 2 , Ryan A. Stewart 1, Yingyun Cai 2 , Shuiqing Yu 2 , Janie Liang 2, Julie Dyall 2 , Jason D. Salter 1 , Harold C. Smith 1,* and Jens H. Kuhn 2,* 1 OyaGen, Inc., 77 Ridgeland Road, Rochester, NY 14623, USA; [email protected] (R.P.B.); [email protected] (R.A.S.); [email protected] (J.D.S.) 2 NIH/NIAID/DCR/Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA; courtney.fi[email protected] (C.L.F.); [email protected] (E.N.P.); [email protected] (Y.C.); [email protected] (S.Y.); [email protected] (J.L.); [email protected] (J.D.) * Correspondence: [email protected] (H.C.S.); [email protected] (J.H.K.); Tel.: +1-585-697-4351 (H.C.S.); +1-301-631-7245 (J.H.K.) † These authors contributed equally to this work. Abstract: Filoviruses, such as Ebola virus and Marburg virus, are of significant human health concern. From 2013 to 2016, Ebola virus caused 11,323 fatalities in Western Africa. Since 2018, two Ebola virus disease outbreaks in the Democratic Republic of the Congo resulted in 2354 fatalities. Although there is progress in medical countermeasure (MCM) development (in particular, vaccines and antibody- based therapeutics), the need for efficacious small-molecule therapeutics remains unmet. Here we describe a novel high-throughput screening assay to identify inhibitors of Ebola virus VP40 matrix protein association with viral particle assembly sites on the interior of the host cell plasma membrane. -
Journal of Virology
JOURNAL OF VIROLOGY Volume 80 September 2006 No. 18 SPOTLIGHT Articles of Significant Interest Selected from This Issue by 8847 the Editors STRUCTURE AND ASSEMBLY Alphavirus Capsid Protein Helix I Controls a Checkpoint Eunmee M. Hong, Rushika Perera, 8848–8855 in Nucleocapsid Core Assembly and Richard J. Kuhn Mutation at Residue 523 Creates a Second Receptor Tatiana Bousse and Toru Takimoto 9009–9016 Binding Site on Human Parainfluenza Virus Type 1 Hemagglutinin-Neuraminidase Protein Proteomic and Biochemical Analysis of Purified Human Elena Chertova, Oleg Chertov, Lori 9039–9052 Immunodeficiency Virus Type 1 Produced from Infected V. Coren, James D. Roser, Charles Monocyte-Derived Macrophages M. Trubey, Julian W. Bess, Jr., Raymond C. Sowder II, Eugene Barsov, Brian L. Hood, Robert J. Fisher, Kunio Nagashima, Thomas P. Conrads, Timothy D. Veenstra, Jeffrey D. Lifson, and David E. Ott Oligomerization of Hantavirus Nucleocapsid Protein: Agne Alminaite, Vera Halttunen, 9073–9081 Analysis of the N-Terminal Coiled-Coil Domain Vibhor Kumar, Antti Vaheri, Liisa Holm, and Alexander Plyusnin Crystal Structure of the Receptor-Binding Protein Head Stefano Ricagno, Vale´rie 9331–9335 Domain from Lactococcus lactis Phage bIL170 Campanacci, Ste´phanie Blangy, Silvia Spinelli, Denise Tremblay, Sylvain Moineau, Mariella Tegoni, and Christian Cambillau GENOME REPLICATION AND REGULATION OF VIRAL GENE EXPRESSION High-Throughput, Library-Based Selection of a Murine Julie H. Yu and David V. Schaffer 8981–8988 Leukemia Virus Variant To Infect Nondividing Cells Temporal Transcription Program of Recombinant Shih Sheng Jiang, I-Shou Chang, 8989–8999 Autographa californica Multiple Nucleopolyhedrosis Virus Lin-Wei Huang, Po-Cheng Chen, Chi-Chung Wen, Shu-Chen Liu, Li- Chu Chien, Chung-Yen Lin, Chao A. -
Receptor-Binding and Oncogenic Properties of Polyoma Viruses Isolated from Feral Mice
Receptor-Binding and Oncogenic Properties of Polyoma Viruses Isolated from Feral Mice John Carroll1[, Dilip Dey1[, Lori Kreisman1[, Palanivel Velupillai1, Jean Dahl1, Samuel Telford2, Roderick Bronson1, Thomas Benjamin1* 1 Department of Pathology, Harvard Medical School, Boston, Massachusetts, United States of America, 2 Department of Tropical Public Health, Harvard School of Public Health, Boston, Massachusetts, United States of America Laboratory strains of the mouse polyoma virus differ markedly in their abilities to replicate and induce tumors in newborn mice. Major determinants of pathogenicity lie in the sialic binding pocket of the major capsid protein Vp1 and dictate receptor-binding properties of the virus. Substitutions at two sites in Vp1 define three prototype strains, which vary greatly in pathogenicity. These strains replicate in a limited fashion and induce few or no tumors, cause a disseminated infection leading to the development of multiple solid tumors, or replicate and spread acutely causing early death. This investigation was undertaken to determine the Vp1 type(s) of new virus isolates from naturally infected mice. Compared with laboratory strains, truly wild-type viruses are constrained with respect to their selectivity and avidity of binding to cell receptors. Fifteen of 15 new isolates carried the Vp1 type identical to that of highly tumorigenic laboratory strains. Upon injection into newborn laboratory mice, the new isolates induced a broad spectrum of tumors, including ones of epithelial as well as mesenchymal origin. Though invariant in their Vp1 coding sequences, these isolates showed considerable variation in their regulatory sequences. The common Vp1 type has two essential features: 1) failure to recognize ‘‘pseudoreceptors’’ with branched chain sialic acids binding to which would attenuate virus spread, and 2) maintenance of a hydrophobic contact with true receptors bearing a single sialic acid, which retards virus spread and avoids acute and potentially lethal infection of the host. -
REVIEW Hepatitis C Virus
DOI:http://dx.doi.org/10.7314/APJCP.2012.13.12.5917 Hepatitis C Virus -Proteins, Diagnosis, Treatment and New Approaches for Vaccine Development REVIEW Hepatitis C Virus - Proteins, Diagnosis, Treatment and New Approaches for Vaccine Development Hossein Keyvani1, Mehdi Fazlalipour2*, Seyed Hamid Reza Monavari1, Hamid Reza Mollaie2 Abstract Background: Hepatitis C virus (HCV) causes acute and chronic human hepatitis infection and as such is an important global health problem. The virus was discovered in the USA in 1989 and it is now known that three to four million people are infected every year, WHO estimating that 3 percent of the 7 billion people worldwide being chronically infected. Humans are the natural hosts of HCV and this virus can eventually lead to permanent liver damage and carcinoma. HCV is a member of the Flaviviridae family and Hepacivirus genus. The diameter of the virus is about 50-60 nm and the virion contains a single-stranded positive RNA approximately 10,000 nucleotides in length and consisting of one ORF which is encapsulated by an external lipid envelope and icosahedral capsid. HCV is a heterogeneous virus, classified into 6 genotypes and more than 50 subtypes. Because of the genome variability, nucleotide sequences of genotypes differ by approximately 31-34%, and by 20-23% among subtypes. Quasi-species of mixed virus populations provide a survival advantage for the virus to create multiple variant genomes and a high rate of generation of variants to allow rapid selection of mutants for new environmental conditions. Direct contact with infected blood and blood products, sexual relationships and availability of injectable drugs have had remarkable effects on HCV epidemiology. -
Defining the Multiplicity and Type of Infection for the Production of Zaire Ebola Virus-Like Particles in the Insect Cell Baculovirus Expression System
DEFINING THE MULTIPLICITY AND TYPE OF INFECTION FOR THE PRODUCTION OF ZAIRE EBOLA VIRUS-LIKE PARTICLES IN THE INSECT CELL BACULOVIRUS EXPRESSION SYSTEM Ana Ruth Pastor, Instituto de Biotecnología, Universidad Nacional Autónoma de México Av. Universidad 2001 Col. Chamilpa, México [email protected] Gonzalo González-Domínguez, Instituto de Biotecnología. Universidad Nacional Autónoma de México Carlos F. Arias, Instituto de Biotecnología. Universidad Nacional Autónoma de México Alejandro Alagón, Instituto de Biotecnología. Universidad Nacional Autónoma de México Octavio T. Ramírez, Instituto de Biotecnología. Universidad Nacional Autónoma de México Laura A. Palomares, Instituto de Biotecnología. Universidad Nacional Autónoma de México Key Words: Ebola virus, ZEBOV-VLP’s, coinfection, hemorrhagic fever, immunogenic response. Ebola virus hemorrhagic fever affects thousands of people worldwide with high mortality rates. The Ebola virus has a short incubation time between 2-21 days and death usually occurs within 4-10 days1. Ebola virus disease is characterized by a sudden onset of fever, weakness, headache, diarrhea and vomiting, internal and external bleeding2. In the Filovirus family, Zaire Ebola virus (ZEBOV) is the most aggressive and virulent species, its fatality rates have been reported to be up to 90%3. Even when important advances in vaccine development have occurred, the need of safe and effective vaccines persists4. An alternative is the production of virus-like particles, which are formed by the recombinant virus structural proteins that self-assemble into highly immunogenic structures5. The ZEBOV contains three main structural proteins: the glycoprotein (GP), the viral matrix protein 40 (VP40) and the nucleoprotein (NP). GP induces humoral and cellular responses by itself but when VP40 is co-expressed, the immune response increases in a mouse model6. -
Structural Basis and Evolution of Glycan Receptor Specificities Within the Polyomavirus Family
RESEARCH ARTICLE Host-Microbe Biology crossm Structural Basis and Evolution of Glycan Receptor Specificities within the Polyomavirus Family Luisa J. Ströh,a* Nils H. Rustmeier,a Bärbel S. Blaum,a Josephine Botsch,a Philip Rößler,a Florian Wedekink,a W. Ian Lipkin,b Nischay Mishra,b Thilo Stehlea,c Downloaded from aInterfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany bCenter for Infection and Immunity, Columbia University, New York, New York, USA cDepartment of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA ABSTRACT Asymptomatic infections with polyomaviruses in humans are common, but these small viruses can cause severe diseases in immunocompromised hosts. New Jersey polyomavirus (NJPyV) was identified via a muscle biopsy in an organ transplant recipient with systemic vasculitis, myositis, and retinal blindness, and hu- http://mbio.asm.org/ man polyomavirus 12 (HPyV12) was detected in human liver tissue. The evolutionary origins and potential diseases are not well understood for either virus. In order to define their receptor engagement strategies, we first used nuclear magnetic reso- nance (NMR) spectroscopy to establish that the major capsid proteins (VP1) of both viruses bind to sialic acid in solution. We then solved crystal structures of NJPyV and HPyV12 VP1 alone and in complex with sialylated glycans. NJPyV employs a novel binding site for a ␣2,3-linked sialic acid, whereas HPyV12 engages terminal ␣2,3- or ␣2,6-linked sialic acids in an exposed site similar to that found in Trichodysplasia on October 12, 2020 by guest spinulosa-associated polyomavirus (TSPyV). Gangliosides or glycoproteins, featuring in mammals usually terminal sialic acids, are therefore receptor candidates for both viruses.